Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

被引：2
|
作者：
Starodub, A.
Cohn, A. L.
Arrowood, C.
Haley, S.
Morse, M.
Uronis, H. E.
Blobe, G. C.
Hsu, S. D.
Zafar, Y.
Hurwitz, H.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
513
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer
    Villalona-Calero, M
    Blum, J
    Diab, S
    Elledge, R
    Khoury, P
    Kraynak, M
    Moczygemba, J
    Kromelis, P
    Impellizeri, K
    Griffin, T
    Von Hoff, D
    Rowinsky, E
    ANNALS OF ONCOLOGY, 1998, 9 : 97 - 97
  • [42] Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study
    Bordonaro, R.
    Calvo, A.
    Auriemma, A.
    Hollebecque, A.
    Rubovszky, G.
    Saunders, M. P.
    Papai, Z.
    Prager, G.
    Stein, A.
    Andre, T.
    Argiles, G.
    Cubillo, A.
    Dahan, L.
    Edeline, J.
    Leger, C.
    Cattan, V.
    Fougeray, R.
    Amellal, N.
    Tabernero, J.
    ESMO OPEN, 2021, 6 (05)
  • [43] Clinical Efficacy of Bevacizumab in Conjunction with Oxaliplatin and Capecitabine in Managing Metastatic Colorectal Cancer
    Zang, J.
    Zhang, X.
    Wang, Qing
    Gan, Jianchen
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 : 290 - 294
  • [44] A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.
    Overman, Michael J.
    Eng, Cathy
    Kee, Bryan K.
    Fogelman, David R.
    Fark, Christine
    Hippert, Rick
    Holter, Scott
    Issa, Jean-Pierre
    Hamilton, Stanley R.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [45] Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    Wolpin, Brian M.
    Clark, Jeffrey W.
    Meyerhardt, Jeffrey A.
    Earle, Craig C.
    Ryan, David P.
    Enzinger, Peter C.
    Zhu, Andrew X.
    Blaszkowsky, Lawrence
    Battu, Subha
    Fuchs, Charles S.
    CLINICAL COLORECTAL CANCER, 2006, 6 (03) : 208 - 213
  • [46] A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
    Fornaro, Lorenzo
    Masi, G.
    Bursi, S.
    Loupakis, F.
    Vasile, E.
    Antonuzzo, A.
    Chiara, S.
    Pfanner, E.
    Di Paolo, A.
    Bocci, G.
    Del Tacca, M.
    Falcone, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (05) : 965 - 969
  • [47] A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
    Lorenzo Fornaro
    G. Masi
    S. Bursi
    F. Loupakis
    E. Vasile
    A. Antonuzzo
    S. Chiara
    E. Pfanner
    A. Di Paolo
    G. Bocci
    M. Del Tacca
    A. Falcone
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 965 - 969
  • [48] A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
    Starling, N.
    Vazquez-Mazon, F.
    Cunningham, D.
    Chau, I.
    Tabernero, J.
    Ramos, F. J.
    Iveson, T. J.
    Saunders, M. P.
    Aranda, E.
    Countouriotis, A. M.
    Ruiz-Garcia, A.
    Wei, G.
    Tursi, J. M.
    Guillen-Ponce, C.
    Carrato, A.
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 119 - U110
  • [49] A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metasetatic or recurrent pancreatic cancer.
    Sym, Sun Jin
    Hong, Junsik
    Jung, Minkyu
    Koo, Yang Seo
    Park, Yeon Ho
    Kim, Koen Kook
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Shin, Dong Bok
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Phase II study of the combination of bevacizumab (Rhumab VEGF) and oxaliplatin plus capecitabine (Xelox) in patients with advanced colorectal cancer
    Sarmiento, R.
    Frustaci, S.
    Bonadonna, A.
    Ravaioli, A.
    Oliviero, G.
    Mattioli, R.
    Tarnburrano, T.
    Gebbia, V
    Agueli, R.
    Torino, F.
    Lo Noce, V
    Veri, A.
    Gasparini, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 85 - 86
12345